NKG2D and DNAM-1 Activating Receptors and Their Ligands in NK-T Cell Interactions: Role in the NK Cell-mediated Negative Regulation of T Cell Responses
Overview
Affiliations
The negative regulation of adaptive immunity is relevant to maintain lymphocyte homeostasis. Several studies on natural killer (NK) cells have shown a previously unappreciated immunomodulatory role, as they can negatively regulate T cell-mediated immune responses by direct killing and by secretion of inhibitory cytokines. The molecular mechanisms of T cell suppression by NK cells, however, remained elusive. Only in the last few years has it become evident that, upon activation, human T cells express MICA-B, ULBP1-3, and PVR, ligands of the activating receptors NKG2D and DNAM-1, respectively. Their expression renders T cells targets of NK cell lysis, representing a new mechanism taking part to the negative regulation of T cell responses. Studies on the expression of NKG2D and DNAM-1 ligands on T cells have also contributed in understanding that the activation of ATM (ataxia-telangiectasia, mutated)/ATR (ATM/Rad3-related) kinases and the DNA damage response is a common pathway regulating the expression of activating ligands in different types of cells and under different conditions. The functional consequences of NKG2D and DNAM-1 ligand expression on activated T cells are discussed in the context of physiologic and pathologic processes such as infections, autoimmunity, and graft versus host disease.
Kaur K, Jewett A Cancer Immunol Immunother. 2025; 74(4):127.
PMID: 40024920 PMC: 11872835. DOI: 10.1007/s00262-025-03956-x.
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A, Tarannum M, Lerias J, Piccinelli S, Borrego L, Maeurer M Cells. 2024; 13(5.
PMID: 38474415 PMC: 10930942. DOI: 10.3390/cells13050451.
Murine models to study human NK cells in human solid tumors.
Parodi M, Astigiano S, Carrega P, Pietra G, Vitale C, Damele L Front Immunol. 2023; 14:1209237.
PMID: 37388731 PMC: 10301748. DOI: 10.3389/fimmu.2023.1209237.
Kumar P, Ranmale S, Mehta S, Tongaonkar H, Patel V, Singh A J Ovarian Res. 2023; 16(1):114.
PMID: 37322531 PMC: 10268537. DOI: 10.1186/s13048-023-01192-4.
Desimio M, Covino D, Rivalta B, Cancrini C, Doria M Cancers (Basel). 2023; 15(6).
PMID: 36980798 PMC: 10047181. DOI: 10.3390/cancers15061914.